Sign in
CompletedNo phase

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS

Key facts

Who runs it
Fondazione Italiana Linfomi - ETS
Where
Italy and Spain15 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
300 people enrolled
Started
28 Aug 2018
Ended
2 Oct 2025
Type of study
Observational
Treatments tested
  • MRD and clonal evolution
Record updated
27 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Diagnosis of IgM monoclonal gammopathy of undetermined significance (Ig-MGUS) or Waldenström's Macroglobulinemia (WM) according to criteria established at the second International Workshop on Waldenström's Macroglobulinemia [1]
  • Age ≥ 18 years
  • Previously untreated patients (only for the prospective cohort)
  • Symptomatic or asymptomatic disease
  • Subject understands and voluntarily signs an informed consent form approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB)

Who cannot take part

  • Active HBV, HCV or HIV infection (antiHBc+ patients with undetectable HBV-DNA are eligible to the study)

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Multicenter retrospective and prospective observational study including patients with WM or IgM-MGUS evaluated at the time of diagnosis and during the disease course using highly sensitive techniques.

The group in the trial

  • Patient enrolled

    Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)

    Treatment: MRD and clonal evolution

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
Record updated
27 August 2026